Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

15.46 -0.54 (-3.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 423,008
Open 15.71
Bid (Size) 15.17 (1)
Ask (Size) 15.42 (5)
Prev. Close 16.00
Today's Range 15.23 - 16.76
52wk Range 0.4100 - 19.69
Shares Outstanding 348,875,959
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
From Agenus
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga

Performance

YTD
+1832.02%
+1832.02%
1 Month
+43.41%
+43.41%
3 Month
+2762.96%
+2762.96%
6 Month
+2135.07%
+2135.07%
1 Year
+754.14%
+754.14%

More News

Read More
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
Via The Motley Fool
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Agenus Announces Virtual Annual Shareholders Meeting
From Agenus Inc.
Via Business Wire
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
Via InvestorPlace
7 Biotech Stocks to Put on Your Breakthrough Radar
Via InvestorPlace
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
From Agenus Inc.
Via Business Wire
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
From Agenus Inc.
Via Business Wire
3 Magnificent Growth Stocks to Buy Hand Over Fist
Via The Motley Fool
Topics Economy
Exposures Interest Rates
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
From Agenus Inc.
Via Business Wire
Agenus (AGEN) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Agenus Reports First Quarter 2024 Results
From Agenus Inc.
Via Business Wire
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Agenus Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
From Agenus Inc.
Via Business Wire
Top 2 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom
Via Benzinga
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
From Agenus Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.